
Sign up to save your podcasts
Or


In this episode of Medsider Radio, we sat down with David Neale, CEO and co-founder of Argá Medtech.
David has three decades of experience bringing medical goods, services, and devices to bear across a range of sectors and in multiple countries. In 2020, he launched Argá Medtech, a multinational company focused on developing new, more efficient ways to treat atrial fibrillation.
In this conversation, David explains how being a multinational company increased their chances of success, and why startups should incorporate economic outcomes into their clinical studies.
Before we jump into the discussion, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with David if you'd rather read it instead.
By Scott Nelson4.7
6868 ratings
In this episode of Medsider Radio, we sat down with David Neale, CEO and co-founder of Argá Medtech.
David has three decades of experience bringing medical goods, services, and devices to bear across a range of sectors and in multiple countries. In 2020, he launched Argá Medtech, a multinational company focused on developing new, more efficient ways to treat atrial fibrillation.
In this conversation, David explains how being a multinational company increased their chances of success, and why startups should incorporate economic outcomes into their clinical studies.
Before we jump into the discussion, I wanted to mention a few things:
If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.
Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market.
This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.
In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you’re interested, go to medsider.com/subscribe to learn more.
Lastly, here's the link to the full interview with David if you'd rather read it instead.

90,967 Listeners

153,555 Listeners

537 Listeners

9,539 Listeners

59 Listeners

49 Listeners

112,408 Listeners

56,513 Listeners

8,549 Listeners

21 Listeners

1,654 Listeners

16,884 Listeners

10,988 Listeners